Home » Authors » Karen Young

Karen Young

Articles

ARTICLES

Gilead Returns Cidecin Rights In Europe; Cubist Considers Options

Sep. 11, 2002

Gilead Returns Cidecin Rights In Europe; Cubist Considers Options

Sep. 11, 2002

Immune Response Cuts Staff To Focus On Remune; CEO Resigns

Sep. 10, 2002

Immune Response Cuts Staff To Focus On Remune; CEO Resigns

Sep. 10, 2002

Versicor Reports Positive Results From Phase II Trial In Infections

Sep. 6, 2002

Versicor Reports Positive Results From Phase II Trial In Infections

Sep. 6, 2002

DNA Sciences, Merck KgaA In Genetic Variant Agreement

Sep. 5, 2002

DNA Sciences, Merck KgaA In Genetic Variant Agreement

Sep. 5, 2002

Sequenom Completes Axiom Purchase, Gains Cell Biology

Sep. 4, 2002

Sequenom Inc. completed its acquisition of Axiom Biotechnologies Inc., paving the way to fold Axiom's cell biology program into Sequenom's gene discovery business. (Bioworld Today)

Sequenom Completes Axiom Purchase, Gains Cell Biology

Sep. 4, 2002

Sequenom Inc. completed its acquisition of Axiom Biotechnologies Inc., paving the way to fold Axiom's cell biology program into Sequenom's gene discovery business. (Bioworld Today)

View All Articles by Karen Young

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...